In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 2.84% at $27.73. The stock's change was less than the S&P 500's daily loss of 0.47%. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.
Shares of the company witnessed a loss of 12.72% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. On that day, Viking Therapeutics, Inc. is projected to report earnings of -$1 per share, which would represent a year-over-year decline of 23.46%.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.47 per share and a revenue of $0 million, signifying shifts of -40.13% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 182, this industry ranks in the bottom 27% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Viking Therapeutics, Inc. (VKTX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).